Adaptive Biotechnologies Corporation Common Stock
Veridion Score
Composite trend over time
Why is ADPT moving today?
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ADPT.
ADPT insider activity
Adaptive Biotechnologies Corporation Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for ADPT.
ADPT contract awards, year to date.
Public federal awards linked to this ticker.
ADPT lobbying filings, year to date.
Registered lobbying filings matched to Adaptive Biotechnologies Corporation Common Stock.